Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone for Excessive Menstruation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Complaint of HMB, including women with fibroids~* Pre-menopausal~* Age 18 years and over~* Describing menstrual cycles every 21- 42 days~* Provide written informed consent prior to any study related procedures~* If of childbearing potential either agree to practice a non-hormonal method of contraception for duration of study or have a partner with a vasectomy~* Workup (Study 1 or 2)- MBL for single screening period is \>= 50mL~* Adaptive Trial (Study 3)- average MBL for two screening menstrual collections is \>= 50mL~Exclusion Criteria:~* Currently breast-feeding~* History or current uterus, cervix, ovarian or breast cancer~* Known severe coagulation disorder~* Glucocorticoid treatment or sex steroid administration by any route in previous 1 month~* Taking prohibited medication -~* Thyroid, renal or liver dysfunction~* Diabetes mellitus~* Treated moderate/severe hypertension~* Psychotic depressive illness~* Rare hereditary galactose intolerance, lactase deficiency or glucose galactose malabsorption (due to lactose content of trial medication)~* Has a problem with alcohol or drug abuse~* Has a mental condition rendering her unable to understand the nature and scope of the study~* Participation in treatment phase in any earlier DexFEM study (1 or 2)~* Is currently enrolled in an investigational drug or device study or participated in such a study within the previous 30 days and is still in exclusion period~* workup study 1, only, an additional exclusion criterion of any contra-indication to MRI

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Dexamethasone (Type: ACTIVE_COMPARATOR): Study 1, and study2(2 arms); Dexamethasone 1.5mg daily Study 3 (adaptive -7 arms): Dexamethasone of 0.4, 0.8, 1.0, 1.2, 1.5, and 1.8 mg total dose per day
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).